BCRO FPCT Introduction

Cell transplantation is a surgical procedure in which an implantation of live tissue fragments of different organs and tissues, of human (allo-, or auto-) or animal (xeno-) origin, from fetal, neonatal, juvenile, or adult stage, is carried out as the therapy of diseases of humans and animals.

It is the only known therapy available to physicians as treatment of many ailments of their patients to accomplish repair or healing of any mal- (or non-) functioning cell type, of any tissue(s) and organ(s), damaged by disease, by injury, or by abnormal growth & development, by

  • Direct stimulation of regeneration of the patient’s own mal- (or non-) functioning cells of any such damaged tissue(s) or organ(s) or by
  • Transplantation of new live cells to replace the function of those damaged or destroyed in the patient’s body.
    Cell transplantation has been used successfully for 85+ years as treatment of many diseases for which modern medicine has had no therapy, or in which ‘state-of-art’ therapies stopped being effective. It is not a ’wonder drug’, or a transplantation of some ’Mother-of-all-Cell’, or ’universal stem cell’, that cures everything.

BCRO Fetal Precursor Cell transplantation or FPCT is the only known therapy to directly stimulate regeneration of the damaged tissues of all organs, or to outright transplant new cells from fetal stage of development, that are prepared by primary cell culture, whereby they lost their immunogenicity, and thus are accepted by the body of the patient as ‘self’, i.e. not rejected.

So prepared fetal precursor cells, i.e. by BCRO (Bio-Cellular Research Organization) method of primary tissue culture, are implanted without immunosuppression, and thereby all complications caused by such drugs are avoided.

Every diseased organ of the body can be treated by fetal precursor cell transplantation, it is just a matter of finding out what type of cells to use for transplantation: that requires knowledge pathophysiology of all diseases, and clinical sense (art), since diagnostic possibilities of current medicine are still inadequate.

The use of immunosuppression has been one of the main reasons why the success rate of cell transplantation has been so low in those lands where the use of immunosuppression has been mandatory. Long-term immunosuppression is not only dangerous to the patients, it is detrimental to fetal cell transplants, because these very young cells are enormously sensitive to any toxins, and that includes immunosuppressants.

Until we learn what life is and can explain various aspects of the function of the living body, we have to be satisfied with the fact that implantation of fetal precursor cell transplants prepared by the ‘state-of-art’ BCRO method does not cause clinically apparent immune reactions.

There are many published medical reports on hundreds of patients showing that changes of laboratory parameters of the immune system function before and after fetal precursor cell transplantation are minimal and statistically not significant, providing fetal precursor cell transplants are prepared ‘state-of-art’.


Prescribed fetal cells for a specific patient do not have to be implanted into damaged organ or tissue, i.e. liver cells into liver, etc.,  they can be implanted into more accessible superficial tissues, as for example under the aponeurosis of the rectus abdominis muscle, or deeply subcutaneously in the gluteal area, because transplanted fetal cells find their way into the damaged organ or tissue from there, as if ‘attracted’ by it. This is called ‘homing’.

Damaged cells of a diseased organ or tissue, e.g. hepatocytes in the cirrhotic liver, myocardial fibers in infarcted myocardium, etc. emit signals to the implanted stem cells “SOS, we need help”, and within 48 – 72 hours hepatoblasts travel from the implantation site to the damaged parts of liver, cardiomyoblasts to the area of myocardial infarct, etc.

Such binding occurs because proteins known as ‘homing receptors’ on the surface of implanted fetal cell have a strong affinity for determinants, called vascular addressins, expresses by high endothelial cells in various target organs. These addressins are characteristic of that organ, and are recognized by a specific type of homing receptor on the surface of implanted fetal cell.

High endothelial venules appear transiently at any site in the body where an injury response is occurring, i.e. in a diseased organ or tissue.

In summary, the implanted cells disappear from the implantation site, with different speed, usually within 48 hours, and if they are labeled by vital staining or radioisotope, we will find them incorporated in the same organ or tissue, following the rules of ‘organospecificity’. According to the ‘Halsted principle’ implanted cells migrate to the ‘place of need’ in accordance with organotropic effect of cell transplants, i.e. the stimulation of the same organ of the recipient by implanted cell transplants, heart by cardiomyoblasts, kidney by epithelial cells of nephron, liver by hepatocytes, etc., as was postulated by Paracelsus already at the beginning of 16th century, but only if that same organ is damaged, not when the same organ or tissue is normal. The more extensive damage of target organ or tissue, the higher proportion of the transplanted cells ‘home’ into that same organ or tissue.

Such direct stimulation can be triggered only by implanted cell transplant of the corresponding organ, but not by transplantation of other cell types.

Since it is rare that only an individual organ is malfunctioning, i.e. usually the whole organ systems are diseased, it is necessary to treat all ailing organs by corresponding cell transplants. The list of cell transplants necessary for treatment of each patient has to be individually designed in terms of cell composition, dosage, date and preferred route of implantation.

Timing of fetal precursor cell transplantation is extremely important: the sooner after the onset of disease it is carried out, the better are the results.

Cell transplantation is a vastly different approach to medical treatment and cannot be immediately understood by the mind accustomed to deal with (chemical) drug therapy.

The therapeutic effect of drugs of chemical origin is not as broad as those of any of the 200+ known types of cells transplanted into a diseased body with insufficient quantity or function of a particular cell type(s).

Fetal Precursor cell transplantation is a surgical procedure indeed, and not a therapy by mass produced drugs. All surgical operations are ‘individualized therapeutic procedures’. Double blind studies have never been used for evaluation of results of surgical procedures. Even cell xeno-transplants are not, and will not, become ‘mass-produced’ therapeutica.